Synopsis
Synopsis
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Actimoxi
2. Amoxicillin
3. Amoxicillin Anhydrous
4. Amoxicillin Monopotassium Salt
5. Amoxicillin Monosodium Salt
6. Amoxicillin Sodium
7. Amoxicillin, (r*)-isomer
8. Amoxicilline
9. Amoxil
10. Amoxycillin
11. Brl 2333
12. Brl-2333
13. Brl2333
14. Clamoxyl
15. Clamoxyl G.a.
16. Clamoxyl Parenteral
17. Hydroxyampicillin
18. Penamox
19. Polymox
20. Trimox
21. Wymox
1. 61336-70-7
2. Larotid
3. Polymox
4. Trimox
5. Utimox
6. Wymox
7. Clamoxyl
8. Amoxil
9. Amoxipen
10. Moxaline
11. Amodex
12. Zimox
13. Robamox
14. Dispermox
15. Novabritine
16. Hiconcil
17. Imacillin
18. Amoxycillin Trihydrate
19. Brl 2333
20. Moxatag
21. 61336-70-7 (hydrate)
22. Topramoxin
23. Amoxyke
24. Atoksilin
25. Demoksil
26. Largopen
27. Moksilin
28. Promoxil
29. Remoxil
30. Damoxy
31. 804826j2hu
32. (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
33. Amoksicillin
34. Kentrocyllin
35. Zamocilline
36. Alfamox
37. Amophar
38. Amoxidal
39. Amoxillat
40. Amoxina
41. Amoxine
42. Flemoxine
43. Galenamox
44. Gramidil
45. Himinomax
46. Izoltil
47. Matasedrin
48. Metifarma
49. Pacetocin
50. Pamocil
51. Paradroxil
52. Siganopen
53. Simplamox
54. Sintopen
55. Velamox
56. Zamocillin
57. Amoran
58. Ciblor
59. Amoxicillin Hydrate
60. Amoxi-wolff
61. Uro-clamoxyl
62. Brl-2333
63. Amoxi-diolan
64. Amox
65. Amoksicillin Forte
66. A-gram
67. Dura Ax
68. Amoxicillin [usan]
69. Amoxicillin-ratiopharm
70. Drg-0075
71. Amoxicillin (as Trihydrate)
72. (2s,5r,6r)-6-((r)-2-amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
73. (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid;trihydrate
74. Amoxicillin Hydrate (1:3)
75. Neotetranase
76. Sawacillin
77. Pasetocin
78. Eupen
79. Amoxil Trihydrate
80. Unii-804826j2hu
81. Alpha-amino-p-hydroxybenzylpenicillin Trihydrate
82. Amoxipen Trihydrate
83. Dispermox (tn)
84. Moxaline Trihydrate
85. Pasetocin (tn)
86. (2s,5r,6r)-6-{[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
87. Amoxicillin (usp)
88. Amoxicillin Pulsys
89. Amoxicillin-trihydrat
90. Amoxicilline (inn)
91. Amoxil (tn)
92. Amoxicillin [usan:usp:inn:ban:jan]
93. (2s,5r,6r)-6-[(2r)-2-amino-2-(4-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
94. Amoxicillin [vandf]
95. Amoxicillin Hydrate (jp17)
96. Amoxicillin [usp-rs]
97. (2s,5r,6r)-6-((r)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid Trihydrate
98. Dtxsid2022599
99. Chebi:51254
100. Amoxicillin [orange Book]
101. Amoxicillin Hydrate [jan]
102. Apc-111
103. Amoxicillin [usp Impurity]
104. Amoxicillin [usp Monograph]
105. Amoxicillin Trihydrate [mi]
106. Prevpac Component Amoxicillin
107. Talicia Component Amoxicillin
108. Mfcd00072029
109. S5298
110. Amoxicillin Trihydrate [vandf]
111. Augmentin Component Amoxicillin
112. Akos015896673
113. Amoxicillin Trihydrate [mart.]
114. Amoxicillin Component Of Prevpac
115. Amoxicillin Component Of Talicia
116. Amoxicillin Trihydrate [who-dd]
117. Amoxicillin Trihydrate [who-ip]
118. Ccg-268878
119. Ks-5338
120. Amoxicillin Component Of Augmentin
121. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate (2s-(2alpha,5alpha,6beta(s*)))-
122. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate(2s-(2alpha,5alpha,6beta(s*)))-
123. Amoxicillin Trihydrate [green Book]
124. Amoxicillin Trihydrate [ep Monograph]
125. Clavulox Component Amoxicillin Trihydrate
126. D00229
127. Amoxicillinum Trihydricum [who-ip Latin]
128. A833170
129. Amoxicillin Trihydrate Component Of Clavulox
130. Q27122483
131. Amoxil Trihydrate;amoxipen Trihydrate;moxaline Trihydrate
132. Amoxicillin Trihydrate, Vetranal(tm), Analytical Standard
133. Amoxicillin, United States Pharmacopeia (usp) Reference Standard
134. Amoxicillin Trihydrate, British Pharmacopoeia (bp) Reference Standard
135. Amoxicillin Trihydrate, European Pharmacopoeia (ep) Reference Standard
136. Amoxicillin Trihydrate, Pharmaceutical Secondary Standard; Certified Reference Material
137. (2s,5r)-6-[[2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid Trihydrate
138. (2s,5r,6r)-6-((r)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicycl(3.2.0)heptane-2-carboxylic Acid Trihydrate
139. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-(((2r)-amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate, (2s,5r,6r)-
140. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-((amino(4-hydroxyphenyl)acetyl)amino)-3,3-dimethyl-7-oxo-, Trihydrate(2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
141. 6beta-[(2r)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic Acid Trihydrate
142. Amoxicillin Trihydrate For Performance Verification, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 419.5 g/mol |
|---|---|
| Molecular Formula | C16H25N3O8S |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 4 |
| Exact Mass | 419.13623594 g/mol |
| Monoisotopic Mass | 419.13623594 g/mol |
| Topological Polar Surface Area | 161 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 590 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
| 1 of 6 | |
|---|---|
| Drug Name | Amoxil |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet; Capsule; Tablet, chewable; For suspension |
| Route | Oral |
| Strength | 875mg; 50mg/ml; 200mg/5ml; 250mg; 125mg/5ml; 400mg/5ml; 125mg; 500mg; 250mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 2 of 6 | |
|---|---|
| Drug Name | Larotid |
| PubMed Health | Amoxicillin (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | MOXATAG (amoxicillin extended-release) tablets for oral administration are provided as blue film-coated, oval shaped tablets that contain 775 mg of amoxicillin as the trihydrate and are printed with MB-111 on one side in black edible ink. Amoxi... |
| Active Ingredient | Amoxicillin |
| Dosage Form | For suspension |
| Route | Oral |
| Strength | 250mg/5ml; 125mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 3 of 6 | |
|---|---|
| Drug Name | Moxatag |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 775mg |
| Market Status | Prescription |
| Company | Pragma Pharms |
| 4 of 6 | |
|---|---|
| Drug Name | Amoxil |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet; Capsule; Tablet, chewable; For suspension |
| Route | Oral |
| Strength | 875mg; 50mg/ml; 200mg/5ml; 250mg; 125mg/5ml; 400mg/5ml; 125mg; 500mg; 250mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 5 of 6 | |
|---|---|
| Drug Name | Larotid |
| PubMed Health | Amoxicillin (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | MOXATAG (amoxicillin extended-release) tablets for oral administration are provided as blue film-coated, oval shaped tablets that contain 775 mg of amoxicillin as the trihydrate and are printed with MB-111 on one side in black edible ink. Amoxi... |
| Active Ingredient | Amoxicillin |
| Dosage Form | For suspension |
| Route | Oral |
| Strength | 250mg/5ml; 125mg/5ml |
| Market Status | Prescription |
| Company | Dr Reddys Labs |
| 6 of 6 | |
|---|---|
| Drug Name | Moxatag |
| Active Ingredient | Amoxicillin |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | 775mg |
| Market Status | Prescription |
| Company | Pragma Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Bioquim: An European GMP-certified company manufacturing bulk APIs, specializing in sterile lyophilization and chemical synthesis.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32811
Submission : 2018-05-15
Status : Active
Type : II
Certificate Number : CEP 2019-244 - Rev 02
Issue Date : 2023-12-18
Type : Chemical
Substance Number : 260
Status : Valid
NDC Package Code : 55657-101
Start Marketing Date : 2005-08-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2020-07-07
Registration Number : 20200707-30-A-341-24
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd
Manufacturer Address : High-tech Industrial Zone, Economic & Technological Development Zone, Datong, Shanxi, China
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-03-14
Pay. Date : 2022-03-04
DMF Number : 36579
Submission : 2021-12-23
Status : Active
Type : II
Certificate Number : CEP 2021-461 - Rev 01
Issue Date : 2023-12-20
Type : Chemical
Substance Number : 260
Status : Valid
NDC Package Code : 55657-101
Start Marketing Date : 2005-08-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2020-07-07
Registration Number : 20200707-30-A-341-24
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd
Manufacturer Address : High-tech Industrial Zone, Economic & Technological Development Zone, Datong, Shanxi, China
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-03-16
Pay. Date : 2022-03-07
DMF Number : 36698
Submission : 2022-02-13
Status : Active
Type : II
NDC Package Code : 55657-101
Start Marketing Date : 2005-08-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2020-07-07
Registration Number : 20200707-30-A-341-24
Manufacturer Name : Sinopharm Weiqida Pharmaceutical Co., Ltd
Manufacturer Address : High-tech Industrial Zone, Economic & Technological Development Zone, Datong, Shanxi, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13772
Submission : 1998-09-01
Status : Inactive
Type : II
Registration Number : 221MF10239
Registrant's Address : 12 BONGEUNSA-RO, 114-GIL, GANGNAM-GU, SEOUL, 135-715 KOREA
Initial Date of Registration : 2009-11-09
Latest Date of Registration :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13498
Submission : 1998-09-01
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13498
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13207
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13201
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13481
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8845
Submission : 1990-11-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13215
Submission : 1998-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12895
Submission : 1998-03-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12904
Submission : 1998-03-18
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11483
Submission : 1995-04-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11481
Submission : 1995-04-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 250MG;EQ 125MG BASE **...DOSAGE - TABLET;ORAL - 250MG;EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50564
DOSAGE - TABLET;ORAL - 500MG;EQ 125MG BASE **...DOSAGE - TABLET;ORAL - 500MG;EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50564
DOSAGE - FOR SUSPENSION;ORAL - 125MG/5ML;EQ 3...DOSAGE - FOR SUSPENSION;ORAL - 125MG/5ML;EQ 31.25MG BASE/5ML
USFDA APPLICATION NUMBER - 50575
DOSAGE - FOR SUSPENSION;ORAL - 250MG/5ML;EQ 6...DOSAGE - FOR SUSPENSION;ORAL - 250MG/5ML;EQ 62.5MG BASE/5ML
USFDA APPLICATION NUMBER - 50575
DOSAGE - TABLET;ORAL - 875MG;EQ 125MG BASE
USFDA APPLICATION NUMBER - 50720
DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML;EQ 2...DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML;EQ 28.5MG BASE/5ML
USFDA APPLICATION NUMBER - 50725
DOSAGE - FOR SUSPENSION;ORAL - 400MG/5ML;EQ 5...DOSAGE - FOR SUSPENSION;ORAL - 400MG/5ML;EQ 57MG BASE/5ML
USFDA APPLICATION NUMBER - 50725
DOSAGE - TABLET;ORAL - 500MG **Federal Regist...DOSAGE - TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50754
DOSAGE - TABLET;ORAL - 875MG **Federal Regist...DOSAGE - TABLET;ORAL - 875MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50754
DOSAGE - FOR SUSPENSION;ORAL - 600MG/5ML;EQ 4...DOSAGE - FOR SUSPENSION;ORAL - 600MG/5ML;EQ 42.9MG BASE/5ML
USFDA APPLICATION NUMBER - 50755
DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RE...DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL - 500MG;500MG;30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50757
DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML **Fe...DOSAGE - FOR SUSPENSION;ORAL - 200MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50760
DOSAGE - FOR SUSPENSION;ORAL - 400MG/5ML
USFDA APPLICATION NUMBER - 50760
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 1GM;...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 62.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50785
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 775M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 775MG
USFDA APPLICATION NUMBER - 50813
DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RE...DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL - 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50824
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Controlled & Modified Release
Thickeners and Stabilizers
Fillers, Diluents & Binders
Disintegrants & Superdisintegrants
Lubricants & Glidants
Direct Compression
Topical
Granulation
Film Formers & Plasticizers
Rheology Modifiers
Co-Processed Excipients
API Stability Enhancers
Empty Capsules
Solubilizers
Coloring Agents
Emulsifying Agents
Vegetarian Capsules
Taste Masking
Chewable & Orodispersible Aids
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
47
PharmaCompass offers a list of Amoxicillin Trihydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Amoxicillin Trihydrate manufacturer or Amoxicillin Trihydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Amoxicillin Trihydrate manufacturer or Amoxicillin Trihydrate supplier.
PharmaCompass also assists you with knowing the Amoxicillin Trihydrate API Price utilized in the formulation of products. Amoxicillin Trihydrate API Price is not always fixed or binding as the Amoxicillin Trihydrate Price is obtained through a variety of data sources. The Amoxicillin Trihydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DisperMox manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DisperMox, including repackagers and relabelers. The FDA regulates DisperMox manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DisperMox API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DisperMox manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DisperMox supplier is an individual or a company that provides DisperMox active pharmaceutical ingredient (API) or DisperMox finished formulations upon request. The DisperMox suppliers may include DisperMox API manufacturers, exporters, distributors and traders.
click here to find a list of DisperMox suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DisperMox DMF (Drug Master File) is a document detailing the whole manufacturing process of DisperMox active pharmaceutical ingredient (API) in detail. Different forms of DisperMox DMFs exist exist since differing nations have different regulations, such as DisperMox USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DisperMox DMF submitted to regulatory agencies in the US is known as a USDMF. DisperMox USDMF includes data on DisperMox's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DisperMox USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DisperMox suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DisperMox Drug Master File in Japan (DisperMox JDMF) empowers DisperMox API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DisperMox JDMF during the approval evaluation for pharmaceutical products. At the time of DisperMox JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DisperMox suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DisperMox Drug Master File in Korea (DisperMox KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DisperMox. The MFDS reviews the DisperMox KDMF as part of the drug registration process and uses the information provided in the DisperMox KDMF to evaluate the safety and efficacy of the drug.
After submitting a DisperMox KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DisperMox API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DisperMox suppliers with KDMF on PharmaCompass.
A DisperMox CEP of the European Pharmacopoeia monograph is often referred to as a DisperMox Certificate of Suitability (COS). The purpose of a DisperMox CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DisperMox EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DisperMox to their clients by showing that a DisperMox CEP has been issued for it. The manufacturer submits a DisperMox CEP (COS) as part of the market authorization procedure, and it takes on the role of a DisperMox CEP holder for the record. Additionally, the data presented in the DisperMox CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DisperMox DMF.
A DisperMox CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DisperMox CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DisperMox suppliers with CEP (COS) on PharmaCompass.
A DisperMox written confirmation (DisperMox WC) is an official document issued by a regulatory agency to a DisperMox manufacturer, verifying that the manufacturing facility of a DisperMox active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DisperMox APIs or DisperMox finished pharmaceutical products to another nation, regulatory agencies frequently require a DisperMox WC (written confirmation) as part of the regulatory process.
click here to find a list of DisperMox suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DisperMox as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DisperMox API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DisperMox as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DisperMox and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DisperMox NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DisperMox suppliers with NDC on PharmaCompass.
DisperMox Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DisperMox GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DisperMox GMP manufacturer or DisperMox GMP API supplier for your needs.
A DisperMox CoA (Certificate of Analysis) is a formal document that attests to DisperMox's compliance with DisperMox specifications and serves as a tool for batch-level quality control.
DisperMox CoA mostly includes findings from lab analyses of a specific batch. For each DisperMox CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DisperMox may be tested according to a variety of international standards, such as European Pharmacopoeia (DisperMox EP), DisperMox JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DisperMox USP).
